308 results on '"Olson, Richard E."'
Search Results
2. Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides
3. Unlocking P(V) : Reagents for chiral phosphorothioate synthesis
4. Synergistic inhibition of Aβ production by combinations of γ-secretase modulators
5. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents
6. B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor
7. Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features
8. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats
9. The Practice of Medicinal Chemistry and its Contributions to Therapy
10. A P(V) platform for oligonucleotide synthesis
11. The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression
12. Synthesis of functionalized derivatives of the gamma-secretase modulator BMS-932481 and identification of its major metabolite
13. An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS–708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog
14. Signal Peptide Peptidase and γ-Secretase Share Equivalent Inhibitor Binding Pharmacology
15. Ex Vivo Occupancy of γ-Secretase Inhibitors Correlates with Brain β-Amyloid Peptide Reduction in Tg2576 Mice
16. Chapter 3 Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease
17. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments
18. Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease
19. Chapter 10. Antiplatelet therapies
20. A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma
21. Novel tricyclic diamines 1. Synthesis of 1,4-diazaisotwistane and 1,4-diazahomoisotwistane as constrained 3-aminoquinuclidine isosteres
22. Novel tricyclic diamines 2. Synthesis of 1,7-diazaisoadamantane, 1,5-diazaisoadamantane and 1,6-diazahomobrendane
23. Hohlraum designs for high velocity implosions on NIF
24. Chapter 33. Plasma Protein Binding of Drugs
25. Effects of thermal conductivity of liquid layer in NIF wetted foam experiments
26. Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
27. Identification and Characterization of Presenilin-independent Notch Signaling
28. γ-Secretase activity is not involved in presenilin-mediated regulation of β-catenin
29. Mutations at the P1 ′ position of Notch1 decrease intracellular domain stability rather than cleavage by γ-secretase
30. Design and synthesis of a novel series of (1′S,2R,4′S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor
31. Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR
32. Development of spiroguanidine-derived α7 neuronal nicotinic receptor partial agonists
33. Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors
34. Design and optimization of tricyclic gamma-secretase modulators
35. Process Optimization for the Large-Scale Preparation of (2S,3aR,7aS)-tert-Butyl Hexahydro-2,5-methanopyrrolo[3,2-c]pyridine-1(4H)-carboxylate, an Intermediate for Nicotinic Acetylcholine Receptor Agonists
36. BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder
37. The Use of Efficiency Indexes in Testing for Scale Economies in the Motor Carrier Industry
38. Motor Carrier Capital Cost and Contemporary Financial Theory
39. Recent Developments
40. Recent Developments
41. Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate
42. Development of X-ray Tracer Diagnostics for Radiatively-Driven Copper-Doped Beryllium Ablators. NLUF FY1999 Report
43. Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE)
44. Design and synthesis of a novel series of (1′ S ,2 R ,4′ S )-3 H -4′-azaspiro[benzo[4,5]imidazo[2,1- b ]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor
45. Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder
46. BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
47. Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists
48. Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship
49. 4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors
50. Chapter Seven - NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.